FDA Brief

Warning letters Biologics

FDA warning letter to

Zhang Medical P.C. dba New Hope Fertility Center

High riskIssued Jun 24, 2022Posted Jul 26, 2022Office of Biological Products Operations – Division 1

New Hope Fertility Center failed to properly screen and test oocyte and semen donors for communicable diseases, FDA says.

What happened

FDA inspected the facility from November 1 to November 30, 2021 and documented significant deviations from rules for human cells, tissues, and cellular/tissue-based products (HCT/Ps). The letter says donors with Zika virus risk factors or missing screening answers were determined eligible, eligibility was sometimes determined before test results, and a donor with a reactive hepatitis B core antibody test was not made ineligible. FDA also cited missing donor eligibility documentation, untimely testing specimens, and inadequate labeling procedures, and said corrective actions after a 2014 warning letter were inadequate.

What FDA found

  1. The firm determined oocyte donors eligible even when they reported Zika virus risk factors.

    21 CFR 1271.75(d)
  2. The firm determined three oocyte donors eligible before receiving required communicable disease test results.

    21 CFR 1271.50(a)
  3. Donor records for an anonymous oocyte donor and a directed semen donor lacked documentation that eligibility was determined.

    21 CFR 1271.50(a)
  4. At least 25 anonymous oocyte donors were missing documentation of answers to required medical-history questions, and the Zika risk-country list in the questionnaire was incomplete.

    21 CFR 1271.75(a)(1)
  5. A directed oocyte donor whose specimen was reactive for hepatitis B core antibody was not determined ineligible.

    21 CFR 1271.80(d)(1)
  6. A communicable disease test specimen from a directed oocyte donor was not collected within the required time around oocyte recovery.

    21 CFR 1271.80(b)

What FDA wants

FDA asks for a written response within 15 working days from receipt outlining specific corrections, supporting documentation, and how recurrence will be prevented; it also says reproductive tissue from donors with incomplete eligibility must stay in quarantine unless FDA grants an exemption.

Who should pay attention

  • fertility clinics that screen or use donor oocytes, semen, or embryos
  • tissue banks and assisted reproduction laboratories
  • recipients of donor gametes or embryos and their clinicians

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Central Coast Multispecialty Medical Group, Inc.

    FDA warns Central Coast Multispecialty Medical Group over incomplete donor screening and eligibility for reproductive tissue.

    High risk
  2. Conceive Fertility Center

    FDA says Conceive Fertility Center in Dallas used incomplete donor screening and testing for reproductive cells.

    High risk
  3. Louisville Reproductive Center

    Louisville Reproductive Center failed to properly test and screen semen donors for infectious diseases, FDA found.

    High risk
  4. Green Valley Fertility Partners

    FDA cited Green Valley Fertility Partners for donor eligibility failures involving oocyte HCT/Ps, including missing communicable disease testing and screening.

    High risk